Plant Name: Miliusa balansae
Taxonomic Information:
Plant ID: NPO28765
Plant Latin Name: Miliusa balansae
Taxonomy Genus: Miliusa
Taxonomy Family: Annonaceae
Plant External Links:
NCBI TaxonomyDB:
1249038
Plant-of-the-World-Online:
73918-1
Used in Medicines:
Unknown.
Geographical Distribution:
Vietnam; China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| ALPL; ALOX15; CBR1; | |
| ACHE; | |
| CA4; CA7; | |
| PPARA; | |
| NFKB1; | |
| FABP3; LMNA; FABP5; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.398E-10 | 9.835E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.087E-10 | 9.835E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.192E-10 | 1.685E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.959E-09 | 8.620E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.850E-09 | 1.010E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.275E-07 | 1.461E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.012E-06 | 8.811E-04 | ALOX15, CBR1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.411E-06 | 1.138E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 2.325E-06 | 1.633E-03 | FABP3, FABP5, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.298E-06 | 2.176E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.313E-06 | 2.635E-03 | CYP19A1, FFAR4, NFKB1, PPARA |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.736E-06 | 2.787E-03 | CYP19A1, CYP1A1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 5.093E-06 | 2.844E-03 | CYP19A1, CYP1A2, CYP1B1, FABP3, FABP5 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.494E-06 | 2.918E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.372E-05 | 6.638E-03 | CYP1A2, CYP2C19 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.661E-13 | 1.439E-10 | CA12, CA1, CA2, CA4, CA7, CA9 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.085E-10 | 3.788E-08 | CYP2C9, CBR1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.213E-08 | 4.518E-07 | CYP2C9, CBR1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.653E-09 | 2.311E-07 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.713E-07 | 5.104E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.585E-06 | 3.374E-05 | CBR1, GAA, ALOX15, AKR1B1, CYP2C19, CYP3A4, CYP19A1, HSD17B10, CYP2C9, CYP1A2, CYP1A1, ALPL, XDH |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 4.126E-07 | 1.025E-05 | FABP3, FABP5, PPARG, PPARA, PPARD |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.036E-05 | 1.929E-04 | CYP2C9, CBR1, ALOX15, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.343E-05 | 2.685E-04 | CDK6, MAPK1, PPARG, HIF1A, TP53, NFKB1, PPARD |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.329E-05 | 1.981E-04 | CDK6, MAPK1, TP53, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.251E-05 | 1.981E-04 | CYP2C9, CYP1A2, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.985E-05 | 2.465E-04 | CDK6, MAPK1, TP53, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.587E-05 | 2.150E-04 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 8.455E-05 | 7.874E-04 | POLB, CDK6, MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.064E-04 | 8.811E-04 | CYP2C9, ALOX15, MAPK1, CYP2C19 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.512E-04 | 1.719E-03 | LMNA, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.065E-04 | 1.538E-03 | MAPK1, PPARA, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.948E-04 | 1.830E-03 | CDK6, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 3.488E-05 | 3.712E-04 | MAPK1, PPARG, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.811E-04 | 1.421E-03 | CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.273E-05 | 8.127E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.538E-04 | 1.719E-03 | CDK6, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.719E-04 | 2.604E-03 | CDK6, CYP1B1, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 3.945E-04 | 2.351E-03 | CDK6, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.675E-04 | 1.733E-03 | MAPK1, NFKB1, PPARD |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.314E-04 | 2.472E-03 | MAPK1, TP53, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.503E-04 | 3.230E-03 | HPGD, PPARG, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.115E-04 | 2.628E-03 | CDK6, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.887E-04 | 4.604E-03 | MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.158E-03 | 5.093E-03 | PPARG, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 8.951E-04 | 4.302E-03 | CDK6, TP53, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 5.115E-04 | 2.628E-03 | CA2, CYP3A4, ABCG2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 2.348E-03 | 8.746E-03 | MAPK1, MAPT, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.507E-03 | 6.416E-03 | MAPK1, HIF1A, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.449E-03 | 8.901E-03 | POLB, TERT, TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.223E-03 | 8.746E-03 | MAPK1, TP53, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.332E-03 | 8.746E-03 | MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.332E-03 | 8.746E-03 | MAPK1, TP53, NFKB1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.979E-03 | 8.189E-03 | GAA, AKR1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.162E-03 | 5.093E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.710E-05 | 4.679E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ACHE; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
